← back to search

Changgong Zhang

Delft University of Technology · NL
Area of research
Pathology and Forensic Medicine · Oncology
Research interest
Research interests include Medicine, Lung cancer, Internal medicine, Chemotherapy, Antibody-dependent cell-mediated cytotoxicity, and Clinical endpoint.
h-index
—
citations
15
works
2
NIH funding
—
primary concept
—
email
✉ Find email ↗

Recent publications

Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial
Cancer Pathogenesis and Therapy 2024cited by 4position: firstdoi
Penpulimab plus anlotinib as second-line treatment for the small cell lung cancer after failure of platinum-based systemic chemotherapy.
Journal of Clinical Oncology 2021cited by 11position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Jianhua Chen · Shenyang Agricultural University2 papers (2021–2024)Qiang Liu · Stanford University2 papers (2021–2024)Liying Gao · University of Illinois Urbana-Champaign2 papers (2021–2024)Jun Zhao · Beijing Institute of Technology2 papers (2021–2024)Rui Wang · Hebei Medical University2 papers (2021–2024)Kailiang Wu · Shanghai Medical College of Fudan University2 papers (2021–2024)Zhongyao Jia · Linyi People's Hospital2 papers (2021–2024)Chunmei Bai · Guangxi University2 papers (2021–2024)Huijuan Wu · Fudan University2 papers (2021–2024)Sheng Yang · Shanxi Medical University1 papers (2021–2021)Yan Sun · Peking University1 papers (2021–2021)Yuankai Shi · Chinese Academy of Medical Sciences & Peking Union Medical College1 papers (2021–2021)Xin Mu · Jilin University1 papers (2021–2021)Jun Wang · Renmin University of China1 papers (2021–2021)Jun Wang · University of Illinois Chicago1 papers (2024–2024)Yuankai Shi · Hunan Cancer Hospital1 papers (2024–2024)Xinlin Mu · Sun Yat-sen University Cancer Center1 papers (2024–2024)Yan Sun · Soochow University1 papers (2024–2024)— · 1 papers (2021–2021)— · 1 papers (2021–2021)